2 results
Approved WMORecruiting
To assess the effect of BLU-5937 vs placebo on 24-hour cough frequencyin adults with RCC (including unexplained chronic cough) and Baseline24-hourcough frequency >=8 coughs/h at Week 12.To determine the safety of BLU-5937 vs placebo in adults…
Approved WMORecruiting
Phase 2 (MF Expansion-Prior JAKi Arm 1 and Add-on to JAKi Arm 2) Primary Objectives:- To evaluate splenic response rate by imaging after 24 weeks of treatment in Cohorts 1B and 2B (i.e., in non-TD cohorts)- To evaluate the rate of conversion from…